Sionna Therapeutics Inc. Common Stock

SION· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$5.96-16.99%

2026-09-18

Financials

Valuation Metrics

Sionna Therapeutics Inc. Common Stock's Market Cap is $269M. At end of 2025 it was $1.64B. Ranked #2928 of 3,121 in US market (top 94%), #1318 of 1,463 on NASDAQ (top 90%), #240 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 90%) by Market Cap.

Investment Metrics(as of 2026-09-18)

Metric	Value	Rank
Size
Market Cap	$269M	US#2,928/3,121 Sec#240/266
Revenue	$0.00	US#2,889/3,121 Sec#196/266
Net Income	$-97M	US—/3,121 Sec—/266
Total Assets	$283M	US#2,927/3,121 Sec#215/266
Net Assets	$266M	US#2,575/3,121 Sec#164/266
Employees	59	US#2,700/3,121 Sec#206/266
Value
P/B	1.01x	US#607/3,121 Sec#20/266
FCF Yield	-36.44%	US—/3,121 Sec—/266
Profitability
ROE	-36.64%	US#2,608/3,121 Sec#124/266
ROA	-34.38%	US#2,915/3,121 Sec#169/266
Financial Health
Debt Ratio	6.57%	US#61/3,121 Sec#29/266
Total Debt	$8M	US#2,862/3,121 Sec#208/266
FCF	$-98M	US#2,626/3,121 Sec#141/266
Cash	$63M	US#2,471/3,121 Sec#212/266
Current Ratio	20.05x	US#121/3,121 Sec#26/266
Performance
1Y Return	-74.34%	US#3,058/3,121 Sec#256/266
1M Return	-4.64%	US#80/3,121 Sec#12/266
From 52W High	-89.16%	US#3,109/3,121 Sec#265/266
1Y MDD	-91.18%	US#3,118/3,121 Sec#265/266
Trading
Volume	3,643,362 shares	US#1,078/3,121 Sec#109/266
Trading Value	$23M	US#2,302/3,121 Sec#189/266
Per Share
EPS	$-2.16	US—/3,121 Sec—/266
BPS	$5.89	US#2,205/3,121 Sec#113/266

Company Info

CEO Michael Cloonan

Employees 59

HQ Waltham, US

Website https://www.sionnatx.com

Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator.